
|Articles|November 15, 2002
IOP-lowering agents evaluated in real-world setting
Pittsburgh-IOP-lowering products evaluated in the "real-world" setting of a clinical practice can provide valuable information for practitioners, according to Evan B. Dreyer, MD, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
2
Corza Medical announces launch of the SensorTek ROP Kit
3
Defining Retinal Vascular Diseases AMD, DME, RVO
4
EyePoint receives second consecutive positive recommendation from DSMC
5


















































.png)


